Dyslipidemia in Patients with Type 2 Diabetes. Relationships between Lipids, Kidney Disease and Cardiovascular Disease (Q35576079)

8 August 2017

1 reference

title

Dyslipidemia in patients with type 2 diabetes. relationships between lipids, kidney disease and cardiovascular disease (English)

1 reference

8 August 2017

Dyslipidemia in Patients with Type 2 Diabetes. Relationships between Lipids, Kidney Disease and Cardiovascular Disease (English)

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

28 March 2024

1 reference

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14598867

28 March 2024

author name string

Joanne Palmisano

2

1 reference

8 August 2017

Wendy P. Battisti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14598867

28 March 2024

William E. Keane

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14598867

28 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14598867

28 March 2024

publication date

1 September 2003

1 reference

full work available at URL

8 August 2017

https://www.degruyter.com/document/doi/10.1515/CCLM.2003.181/pdf

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Clinical Chemistry and Laboratory Medicine

28 March 2024

published in

1 reference

8 August 2017

41

1 reference

8 August 2017

9

1 reference

8 August 2017

1174-1181

1 reference

Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S.

8 August 2017

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Diabetes and decline in heart disease mortality in US adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

ABC of diabetes: Cardiovascular disease, hypertension, and lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Renal disease and hypertension in non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Insulin resistance implications for type II diabetes mellitus and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Diabetes, hyperlipidemia, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Management of dyslipidemia in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Low-density lipoprotein and oxidised low-density lipoprotein: their role in the development of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Statins and angiotensin II-induced vascular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Management of dyslipidemia in children and adolescents with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Health care and health status and outcomes for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2003.181

Is insulin really a heart disease risk factor

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

28 March 2024

4

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

28 March 2024

13

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?

28 March 2024

19

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

28 March 2024

21

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

28 March 2024

23

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density

28 March 2024

25

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

28 March 2024

26

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

28 March 2024

Heart failure monitor

27

2

14

Ginsberg HN

2001

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men

28 March 2024

30

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Proteinuria: its clinical importance and role in progressive renal disease.

28 March 2024

31

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Progression of renal failure and lipids--is there evidence for a link in humans?

28 March 2024

32

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation

28 March 2024

33

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Microalbuminuria predicts mortality in non-insulin-dependent diabetics

28 March 2024

35

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects?

28 March 2024

39

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

28 March 2024

50

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

28 March 2024

51

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice

28 March 2024

54

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate

28 March 2024

59

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study

28 March 2024

60

1 reference

https://api.crossref.org/works/10.1515/CCLM.2003.181

28 March 2024

Identifiers

1 reference

release_ybvk2m4apfbrjkdetoiwzfzgni

8 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ybvk2m4apfbrjkdetoiwzfzgni

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference